基本信息 产品详情 公司简介 推荐产品
网站主页 PTC-209HBR 化合物 PTC-209 HBr
  • 化合物 PTC-209 HBr|T6178|TargetMol

化合物 PTC-209 HBr|T6178|TargetMol

PTC-209 hydrobromide
1217022-63-3
385 1mg 起订
849 5mg 起订
2530 25mg 起订
上海 更新日期:2025-11-17

TargetMol中国(陶术生物)

VIP4年
联系人:邵小姐
手机:4008200310 拨打
邮箱:marketing@tsbiochem.com

产品详情:

中文名称:
化合物 PTC-209 HBr
英文名称:
PTC-209 hydrobromide
CAS号:
1217022-63-3
品牌:
TargetMol
产地:
美国
保存条件:
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
纯度规格:
99.91%
产品类别:
抑制剂
货号:
T6178

Product Introduction

Bioactivity

名称PTC-209 hydrobromide
描述PTC-209 hydrobromide (PTC-209 HBr) is the hydrobromide salt of PTC-209, which is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM, and results in irreversible reduction of cancer-initiating cells (CICs).
细胞实验To determine whether pretreatment with the inhibitor affects tumor cell growth, cells are plated with the inhibitor for 4 d in vitro and plated in limiting doses in vitro without adding further inhibitor. Trypan blue exclusion is used to count viable cells. The in vitro sphere-initiating cell frequency is calculated after inhibitor treatment by evaluating the number of wells containing spheres. For the experiments where LDAs are set up following recovery of PTC-209 treated cells, 6-well plates were seeded with 1E6 cells per well and incubated overnight. Cells are subsequently treated for 4 d in triplicate with either DMSO vehicle or PTC-209 (0.01, 0.1, 1 and 10 μM). Drug treatments are washed off and 4 mL fresh suspension medium added to all wells. To assess cell viability following the 4 d treatment window, cells are trypsinized and counted at 0, 24, 72 and 120 h after removal of the drug. Long-lasting effects of the drug treatment on sphere-forming ability are assessed by plating LDAs (50,000, 10,000, 1,000,100, 10 and 1 cell per well) using the cells obtained 120 h after the 4-d drug treatment.(Only for Reference)
激酶实验Untranslated region-mediated luciferase reporter expression: HEK293 cells are transfected with a GEMS reporter vector that contains the luciferase open-reading frame flanked by and under post-transcriptional control of the BMI-1 5′ and 3′ UTRs. The resulting stable cells (F8) are treated with PTC-209 or vehicle control overnight, and then luciferase reporter activity is determined using Bright-Glo assays. The assays are run in triplicate for each point, and the percentage of inhibition was calculated against vehicle control.
体外活性PTC-209在人类结直肠癌细胞HCT116和人类纤维肉瘤细胞HT1080中同时抑制UTR介导的报告基因表达和内源性BMI-1表达。PTC-209通过BMI-1依赖的方式减缓结直肠肿瘤细胞生长。此外,PTC-209还通过不可逆的生长抑制作用损害结直肠癌起始细胞(CICs)。[1]
体内活性PTC-209(60 mg/kg/天,皮下注射)有效抑制了肿瘤组织中BMI-1的产生,并在带有初级人类结肠癌异种移植物、人类结肠癌细胞系LIM1215或HCT116异种移植物的小鼠中停止了已建立肿瘤的生长。PTC-209还在体内减少了功能性结直肠CICs的频率。[1]
存储条件store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
溶解度Ethanol : <1 mg/mL
H2O : <1 mg/mL
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (5.73 mM), Sonication is recommended.
DMSO : 93 mg/mL (161.43 mM), Sonication is recommended.
关键字tumor | PTC-209 Hydrobromide | PTC209 Hydrobromide | PTC209 hydrobromide | PTC-209 | PTC209 | PTC 209 Hydrobromide | PTC 209 hydrobromide | PTC 209 | lung | Inhibitor | inhibit | HEK293T | colon | CICs | cells | cancer-initiating | breast | BMI-1 | BMI1 | Autophagy | anti-myeloma
相关产品Guanidine hydrochloride | Naringin | Valproic Acid | Taurine | Gefitinib | Aceglutamide | Hydroxychloroquine | Curcumin | Stavudine | Salicylic acid | Paeonol | Sodium 4-phenylbutyrate
PTC-209 HBr|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。

成立日期 (13年)
注册资本 566.265100万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

化合物 PTC-209 HBr相关厂家报价

  • PTC-209;
  • PTC-209;
  • 湖北诺迪纳生物技术有限公司
  • 2025-04-08
  • 询价
  • PTC-209
  • PTC-209
  • 广州贝尔卡生物科技有限公司
  • 2024-03-04
  • 询价
内容声明
拨打电话 立即询价